14-3-3η Protein, Disease Activity and Bone Mineral Density, in Female Patients With Rheumatoid Arthritis
NCT ID: NCT03999528
Last Updated: 2020-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2019-05-01
2019-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
14.0- 3.0- 3.0- η Protein With Rheumatoid Arthritis
NCT05366608
Accuracy of CBC Derived Markers Against CRP and ESR in Detecting Active Rheumatoid Arthritis in Upper Egypt
NCT07149194
Adherence Rate to DMARDS in Egyptian Patients With RA
NCT03316027
The Relationship Between Rheumatoid Arthritis and Osteoporosis and Factors Contributing to This Connection
NCT06038292
Rheumatoid Arthritis Disease Activity and Sub Clinical Atherosclerosis
NCT03821090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Clinical assessment, WT, Height ,BMI, parity, medications,
* DAS 28.
* Serum 14-3-3η protein.
* DEXA scan.
Grouping:
* Group I: RA Patients with low BMD.
* Group II: RA Patients with normal BMD.
* Group III: normal control.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
study group
RA Patients
14-3-3η Protein assay
blood sampling for assessment of serum 14-3-3η Protein
control group
normal control
14-3-3η Protein assay
blood sampling for assessment of serum 14-3-3η Protein
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
14-3-3η Protein assay
blood sampling for assessment of serum 14-3-3η Protein
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Premenopausal females.
* On conventional DMARD with maximum 5 mg steroids.
Exclusion Criteria
* Previous antiresorptive treatment, or bone anabolics.
* High dose corticosteroid.
* Chronic renal or kidney disease.
* Medications affecting bone metabolism.
* Thyroid or adrenal dysfunction,
16 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Al-Azhar University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Abogamal
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AHMED ABOGAMAL
Role: STUDY_CHAIR
Al-Azhar Faculty of medicine- Cairo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al-Azhar Faculty of medicine, Rheumatology Department
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Rheu-med.9med.research
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.